Skip to main content
. 2020 May 29;10(4):673–697. doi: 10.1016/j.jcmgh.2020.05.007

Figure 18.

Figure 18

MDMs from IL23R–R381/Q381 heterozygote carriers show reduced bacterial uptake and intracellular bacterial clearance relative to R381/R381 MDMs. MDMs from R381/R381 or R381/Q381 carriers (n = 10/genotype) were left untreated or treated with (A–G) 10 ng/mL IL23 or (H–N) 100 μg/mL muramyl dipeptide (MDP). (A and H) Summarized cell surface IL23R (mean fluorescence intensity [MFI]) at the indicated times. (B and I) After 48 hours of treatment, bacterial uptake was assessed (MFI). (C and J) Fold phospho-PDK1 at 15 minutes. (D and K) ROS and p47phox induction at 48 hours (MFI). (E, F, L, and M) The indicated proteins were assessed at 48 hours (MFI). (G and N) After 48 hours of treatment, intracellular bacterial clearance was assessed (CFU). Means + SEM. Significance was between R381– and Q381–IL23R MDMs for each respective treatment condition. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, †P < 1 × 10-4, and ††P < 1 × 10-5. Tx, treatment.